Internship

Vertex Fall 2025 Co-op

Operational Excellence

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

No H1B Sponsorship

Providence, RI, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Ability to examine an issue from diverse perspectives (safety, compliance, automation, equipment, process, and people) to best understand and resolve the root cause.
  • Ability to work cross-functionally and collaborate effectively.
  • Excellent communication, collaboration, and team skills.
  • Excellent communication skills and detailed note taking ability.
  • Experience with Office 365 Suite of programs (SharePoint, Excel, Word, Teams)
  • Legal authorization to work in the United States, now and in the future.
  • Candidate must be enrolled in an advanced degree program if graduating before July 2025.
  • Candidate must be available to work full-time, 40 hours per week from July - December 2025.
Responsibilities
  • Measure critical performance indicators such as process yield, lead time, machine outputs, product/process flow to foster data driven decision making.
  • Participate in and/or lead root cause investigations using facts to drive robust solutions to complex problems.
  • Analyze data to show trending of performance over time.
  • Assess processes and build reports to communicate current state measures.
  • Utilize and develop Lean/6σ competencies to drive improvements to manufacturing processes.
  • Author and submit revisions to controlled documents.
  • Author and revise records in the quality management system to support changes.
  • Deliver training to personnel as required.
Desired Qualifications
  • Microsoft Vizio and Power BI experience a plus.
  • Lean 6σ education/experience a plus.
  • Manufacturing experience a plus.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).